Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738620 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL737575 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL738738 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL737061 | 0.75 | — | — | |
| SCHEMBL3168997 | 0.75 | — | — | |
| SCHEMBL23581363 | 0.75 | — | — | |
| SCHEMBL26112778 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL26112782 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL14862483 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1CYP2A13HPGDL3MBTL1 | |
| SCHEMBL735494 | 0.72 | FYN (0.41) | ALDH1A1L3MBTL1L3MBTL3OPRL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | claimed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | claimed |
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3532470-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | Rigel Pharmaceuticals, Inc. (US) | 2019-09-04 | — | — | EP | claimed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | claimed |
| WO-2018089199-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | claimed |
| US-11993594-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3860980-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20210179601-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | MAP3K1, PIK3CA, MAP3K5 | SMN1; SMN2 4614/4885ALDH1A1 3392/4885CYP2A13 4536/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | SMN1; SMN2 2278/4885ALDH1A1 1717/4885CYP2A13 946/4885 |
| US-20210179601-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885ALDH1A1 1451/4885CYP2A13 4393/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | SMN1; SMN2 2656/4885ALDH1A1 1934/4885CYP2A13 505/4885 |
| US-11993594-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885ALDH1A1 1451/4885CYP2A13 4393/4885 |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885ALDH1A1 1451/4885CYP2A13 4393/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | SMN1; SMN2 3099/4885ALDH1A1 3407/4885CYP2A13 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.